They can raise money against the patents or worse case scenario, sell the patents. NSPX has already successfully completed 4 Phase-2 clinical trials. It can carry on as stated as a going concern until the 3rd Quarter of 2020 with its current finances. That gives it time to either find a buyer or partnership deal IMO.
Also, CEO has not received any financial compensation (salary) since being appointed. If there was nothing here, why would anyone in their right mind accept to work without a salary?
News 
Market Data 
Discover 
